Patient P-02117

Synthetic patientMETA-24 · Day 178 · 55–64 · M · baseline S07Steering view · 3D Open companion preview

Therapy response

Favorable

Tolerance

Deteriorating

GI state

Favorable

Inflammatory state

Favorable

Nutritional resilience

Declining

Discontinuation risk

15%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S07

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days

Toxicity+12
Nutritional resilience-10
Treatment adherence+3
Inflammatory activity+2

What helped?

No interventions yet.

LIFE OS recommendation

No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

72 min

stable · -1.0 vs previous 14 d

Sleep duration

Wearable

7.6 h

stable · -0.1 vs previous 14 d

Energy level

Daily log

6.6/10

stable · -0.2 vs previous 14 d

Steps

Wearable

8,753

stable · +158 vs previous 14 d

GI burden

Companion

17.4/100

worsening · +2.7 vs previous 14 d

Adherence

Companion

93.3 %

stable · +2.5 vs previous 14 d

Sleep quality

Wearable

49.1/100

stable · -1.4 vs previous 14 d

Glucose, CGM daily mean

CGM

119 mg/dL

stable · -2.7 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading drifting · 88 from the failing basin, 2 from restoration.

Would help

No untried action with strong evidence. Compose one from primitives.
More protein
GI -2.6 next day on high-intake days · n 23

Would not help

Keep ultra-processed low
GI +2.1 next day on high-intake days · n 19

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-2.6supporter · 95%
Ultra-processed food
+2.1detractor · 79%
Dietary fat load
-1.3no signal · 29%
Simple carbohydrates
-1.2no signal · 44%
Alcohol
+1.1no signal · 29%
Histamine load
-1no signal · 40%
Insoluble fibre
+0.6no signal · 24%
Caffeine
+0.6no signal · 21%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑60
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- WearableHRV 33 ms, trending down
Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3.9 · butyrate capacity 75/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 31 ms
Sleep: 8.1 h
Steps: 8,440
Resting HR: 59 bpm

Daily log: GI score 17, nutritional resilience 64, adherence 93.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Keep fibre steady; no new sources this week
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02555	45%	S01	AD-05	no change	79
P-02277	37%	S05	AD-05	improved	92
P-02282	38%	S01	BR-03	no change	88
P-02013	37%	S14	BR-03	no change	94
P-02193	34%	S11	CR-01	improved	87
P-02354	34%	S01	CR-01	improved	78
P-02081	46%	S20	DT-01	no change	88
P-02565	40%	S09	DT-01	no change	79
P-02518	35%	S17	DT-01	improved	68
P-02126	33%	S16	DT-01	improved	59
P-02462	32%	S12	DT-01	improved	65
P-02218	31%	S01	DT-01	improved	61